Peptide-major histocompatibility complex on leukemic B-cell

Peptide-major histocompatibility complex (MHC) complexes on leukemic B cells are molecular structures formed by the binding of intracellularly processed peptides (derived from endogenous proteins, including mutated or tumor-specific antigens) to MHC class I or II molecules on the surface of B cells. In the context of leukemia, these complexes display leukemia-associated or mutated peptide fragments, which can be recognized by T cell receptors, enabling immune surveillance or therapeutic targeting. Presentation via MHC class II enables stimulation of CD4+ helper T cells, while class I allows cytotoxic CD8+ T cell activation[1][2][3][4][5][7]. In B cell malignancies, unique idiotype-derived peptides (from the B cell receptor) can also be presented on MHC molecules, serving as neoantigens and potential therapeutic targets. These complexes underpin emerging immunotherapies including TCR-mimetic antibodies and engineered TCR cell therapies designed to specifically recognize leukemia-associated peptide-MHC on malignant B cells, although challenges include safety, antigen heterogeneity, and immune evasion.

Other names

Peptide-MHC complex on B-cellpMHC complex on leukemic B-cellAntigenic peptide-MHC complex on B cell

Immune recognition and targeting by T cells (CD4+ and CD8+ variants) via T cell receptors recognizing specific peptide-MHC combinations. Potential targeting by TCR-mimetic bispecific antibodies or TCR-engineered T cell therapies.